Hydroxamic acid derivative as inhibitor of the formation of soluble human CD23
US6673965B1 · kind B1 · utility
10Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 16, 2002 |
| Grant date | Jan 6, 2004 |
| Priority date | — |
| Expiry date | Jul 16, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C237/22
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound of formula (I) wherein:R isopropyl;n is 0;R1 is naphthylmethyl;R2 is t-butyl; andR3 is methyl;is useful in the treatment of disorders mediated by s-CD23.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.